Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340745 | 0.83 | MAPT (0.50) | TP53CYP3A4TSHRKDM4EMAPT | |
| SCHEMBL22347554 | 0.82 | CYP3A4 (0.50) | TP53CYP3A4TSHRALDH1A1MAPK1 | |
| SCHEMBL4101483 | 0.82 | TSHR (0.46) | TP53CYP3A4TSHRKDM4EMAPT | |
| SCHEMBL29218081 | 0.81 | LOXL2 (0.40) | TP53CYP3A4TSHRKDM4EMAPT | |
| SCHEMBL2144434 | 0.79 | LOXL2 (0.43) | TP53KDM4EMAPTGAAALDH1A1 | |
| SCHEMBL3817033 | 0.78 | NQO1 (0.48) | TP53CYP3A4TDP1TSHRMAPT | |
| SCHEMBL129096 | 0.78 | UHRF1 (0.48) | KDM4EALDH1A1NPC1RAB9ALOX | |
| SCHEMBL23462840 | 0.78 | ASIC3 (0.40) | TP53KDM4EMAPTGAAALDH1A1 | |
| SCHEMBL5323724 | 0.78 | LOX (0.42) | TSHRLOXLOXL2NOS3NOS1 | |
| SCHEMBL16265338 | 0.78 | LOXL2 (0.42) | TP53CYP3A4KDM4EMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4615838-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024099898-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| WO-2021188907-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20170305861-A1 | HETEROARYL COMPOUNDS COMPRISING NITROGEN AND USE THEREOF | IMMUNOMET THERAPEUTICS, INC (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3125895-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015154023-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX DISCOVERY, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| EP-1842847-A1 | PROCESS FOR PRODUCTION OF 5-CHLORO-2,4-DIHYDROXYPYRIDINE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-0819118-B1 | POTASSIUM ION CHANNEL BLOCKERS | POLYCHIP PHARMACEUTICALS PTY (AU) | 2002-09-18 | — | — | EP | disclosed |
| US-5929082-A | SULFONYL(THIO)UREA AND SULFONYLGUANIDINE COMPOUNDS; TREATMENT OF DIABETES, CARDIAC ARRHYTHMIAS, ISCHEMIA, HYPOXIC CARDIOVASCUALR DISORDERS AND CANCER | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 1999-07-27 | — | — | US | disclosed |
| EP-0819118-A4 | POTASSIUM ION CHANNEL BLOCKERS | POLYCHIP PHARMACEUTICALS PTY (AU) | 1998-04-29 | — | — | EP | disclosed |
| EP-0819118-A1 | POTASSIUM ION CHANNEL BLOCKERS | Polychip Pharmaceuticals Pty. Ltd. (AU) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996030341-A1 | POTASSIUM ION CHANNEL BLOCKERS | POLYCHIP PHARMACEUTICALS PTY. LTD. (AU) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | TP53 4059/4885CYP3A4 826/4885TDP1 3206/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | TP53 4593/4885CYP3A4 741/4885TDP1 4595/4885 |
| US-20170305861-A1 | HETEROARYL COMPOUNDS COMPRISING NITROGEN AND USE THEREOF | MKI67, NUDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TP53 254/4885CYP3A4 101/4885TDP1 4318/4885 |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | TP53 3442/4885CYP3A4 4254/4885TDP1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.